Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O.,
Ashoori, A., Corder, A., et al. (2015) Human Epidermal Growth Factor Receptor 2 (HER2) –Specific
Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin
Oncol 33, 1688-1696.
Beatty, G.L., O'Hara, M.H., Lacey, S.F., Torigian, D.A., Nazimuddin, F., Chen, F., Kulikovskaya, I.M.,
Slulen, M.C., McGarvey, M., Nelson, A.M., et al. (2019) Activity of Mesothelin-specific Chimeric
Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology
155, 29-32.
Behr, T.M., Sharkey, R.M., Juweid, M.I., Dunn, R.M., Ying, Z., Zhang, C.H., Siegel, J.A., Gold, D.V.
and Goldenberg, D.M. (1996) Factors influencing the pharmacokinetics, dosimetry, and diagnostic
accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing
tumors. Cancer Res 56, 1805-1816.
Berger, R., Yehudar, R.R., Slama, G., Landes, S., Kneller, A., Leiba, M., Michowitz, M.K., Shimoni, A.
and Nagler, A. (2008) Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody
Interacting with PD-1, in Patients with Advanced Hematologic Malignancies. Clin Cancer Res 14, 30443051.
Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., Stankevich, E., Pons,
A., Salay, T.M., McMiller, T.L., et al. (2010) Phase I study of single-agent anti-programmed death-1
(MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic
correlates. J Clin Oncol 28, 3167-3175.
Burris, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps, M.C.,
Portenoy, R.K., Storniolo, A.M., Tarasoff, P., et al. (1997) Improvements in survival and clinical benefit
with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial. J
Clin Oncol 15, 2403-2413.
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.L.,
Bourgade, S., Fouchardière, C., et al. (2011) FOLFIRINOX versus Gemcitabine for Metastatic
Pancreatic Cancer. N Engl J Med 364, 1817-1825.
49
Cros, J., Raffenne, J., Couvelard, A. and Poté, N. (2018) Tumor geneity in Pancreatic Adenocarcinoma.
Pathobiology 85, 64-71.
Denk, H., Tappeiner, G., Eckerstorfer, R., Holzner, J. H. (1972) Carcinoembryonic antigen (CEA) in
gastrointestinal and extragastrointestinal tumors and its relationship to tumor-cell differentian. Int J cancer
10, 262-273.
Erstad, D.J., Sojoodi, M., Taylor, M.S., Ghoshal, S., Razavi, A.A., O'Regan, K.A., Bardeesy, N., Ferrone,
C.R., Lanuti, M., Caravan, P., et al. (2018) Orthotopic and heterotopic murine models of pancreatic
cancer and their different responses to FOLFIRINOX chemotherapy. Dis Model Mech 11, dmm034793.
Eshhar, Z., Bach, N., Fitzer-Attas, C.J., Gross, G., Lustgarten, J., Waks, T. and Schindler, D.G. (1996)
The T-body approach : potential for cancer immunotherapy. Springer Semin Immunopathol 18, 199-209.
Feng, K., Liu, Y., Guo, Y., Qiu, J., Wu, Z., Dai, H., Yang, Q., Wang, Y. and Han W. (2018) Phase I
study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract
cancers and pancreatic cancers. Protein Cell 9, 838-847.
Girgis, M.D., Olafsen, T., Kenanova, V., McCabe, K.E., Wu, A.M. and Tomlinson, J.S. (2011)
Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI
Res 1, 24.
Gross, G. (1995) Chimeric T cell receptors specific to a B-lymphoma idiotype : a model Search results.
Biochem Soc Trans 23, 1079-1083.
Gansauge, S., Gansauge, F. and Beger, H.G. (1996) Molecular oncology in pancreatic cancer. J Mol Med
74, 313-320.
Heyman, B. and Yang, Y. (2019) Chimeric antigen receptor T cell therapy for solid tumors: Current
status, obstacles and future strategies. Cancers 11, 1-21.
Hoff , D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., Seay, T., Tjulandin, S.A., Ma,
W.W., Saleh, M.N., et al. (2013) Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus
Gemcitabine. NEJM 369, 1691-1703.
50
Jindal, V., Arora, E., Masab, M. and Gupta, S. (2018a) Chimeric antigen receptor T cell therapy in
pancreatic cancer: from research to practice. Med Oncol 35, 84.
Jindal, V., Arora, E. and Gupta, S. (2018b) Challenges and prospects of chimeric antigen receptor T cell
therapy in solid tumors. Med Oncol 35, 87.
Katz, S.C., Burga, R.A., McCormack, E., Wang, L.J., Mooring, W., Point, G.R., Khare, P.D., Thorn, M.,
Ma, Q., Stainken, B.F., et al. (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial
chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Cli Can Res 21, 3149-3159.
Lee, J.M., Fauceglia, P., Lee, N., Parsanian, L.C., Lin, Y.G., Gayther, S.A. and Lawrenson, K. (2013) A
three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian
cancer cells in vitro. Lav Invest 93, 528-542.
Lim, W.A. and June, C.H. (2017) The Principles of Engineering Immune Cells to Treat Cancer. Cell 168,
724-740.
Luca, A.C., Mersch, S., Deenen, R., Schmidt, S., Messner, I., Schäfer, K.W., Baldus, S.E., Huckenbeck,
W., Piekorz, R.P., Knoefel, R.F., et al. (2013) Impact of the 3D Microenvironment on Phenotype, Gene
Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines. PLoS ONE 8, e59689.
Majzner, R.G. and Mackall, C.L. (2018) Tumor antigen escape from car t-cell therapy. Cancer Discov 8,
1219-26.
Markley, J.C. and Sadelain, M. (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human
T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508-3519.
Martinez, M. and Moon, E.K. (2019) CAR T cells for solid tumors: New strategies for finding, infiltrating,
and surviving in the tumor microenvironment. Front Immunol 10, 128.
Meng, Q. (2010) Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity.
Expert Opin Drug Metab Toxicol 6, 733-746.
Moon, E.K., Wang, L.C., Douglas, V., Dolfi, C.B., Wilson, Ranganathan, R., Sun, J., Scholler, K.J., Puré,
51
E., Milone, M.C., et al. (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy
of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20, 4262-4273.
Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M. and Rosenberg, S.A. (2010) Case
report of a serious adverse event following the administration of t cells transduced with a chimeric antigen
receptor recognizing ERBB2. Mol Ther 18, 843-851.
Nakajima, M., Sakoda, Y., Adachi, K., Nagano, H. and Tamada, K. (2019) Improved survival of
chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed
cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer Sci 110, 3079-3088.
Neelapu, S.S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F.L., Komanduri, K.V., Lin,
Y., Jain, N., Daver, N., et al. (2018) Chimeric antigen receptor T-cell therapy-assessment and
management of toxicities. Nat Rev Clin Oncol 15, 47-62.
Newick, K., O'Brien, S., Moon, E., Albelda, S.M. (2016) CAR T Cell Therapy for Solid Tumors. Annu
Rev Med 68, 139-152.
Oxnard, G.R., Thress, K.S., Alden, R.S., Lawrance, R., Paweletz, C.P., Cantarini, M., Yang, J.C.H.,
Barrett, J.C. and Jänne, P.A. (2016) Association between plasma genotyping and outcomes of treatment
with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 34, 3375-3382.
Parkhurst, M.R., Yang, J.C., Langan, R.C., Dudley, M.E., Nathan, D.A.N., Feldman,.S.A., Davis, J.L.,
Morgan, R.A., Merino, M.J., Sherry, R.M., et al. (2011) T cells targeting carcinoembryonic antigen can
mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19, 620626.
Pierre, B., Catia, T., Patrick, C., Christophe, L., Etienne, D.P., Benoît, J.V.E., Alexander, K. and Thierry,
B. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
Science 254, 1643-1647.
Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M. and Matrisian, L.M. (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and
Pancreas Cancers in the United States. Cancer Res 74, 2913-2921.
52
Rebecca, C.L., Michael, C.K., Stefanie, R.B., Nicholas, J.H., Paula, M.L., Amanda, A.B., Irene, S., Mark,
B.L., Korneel, G., Trisha, R.B., et al. (2022) CAR T cell killing requires the IFNγR pathway in solid but
not liquid tumours. Nature 604, 563-570.
Sugiura, H., Ishikura, H., Omi, M., Kaji, M., Iwai, K., Kishimoto, T., Takahashi, T., Kimura, C., Kato, H.
and Yoshiki, T. (1994) Lymphokine-activated killer cytotoxicity against pancreas adenocarcinoma cell
lines and vascular endothelial cells. Pathol Int 44, 688-696.
Tanyi, J.L., Haas, A.R., Beatty, G.L., Morgan, M.A., Stashwick, C.J., O'Hara, M.H., Porter, D.L., Maus,
M.V., Levine, B.L., Lacey, S.F., et al. (2015) Abstract CT105: Safety and feasibility of chimeric antigen
receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin
expressing cancers. Cancer Res 75, CT105.
Terai, K., Jiang, M., Tokuyama, W., Murano, T., Takada, N., Fujimura, K., Ebinuma, H., Kishimoto, T.,
Hiruta, N., Schneider, W.J., et al. (2016) Levels of soluble LR11/SorLA are highly increased in the bile
of patients with biliary tract and pancreatic cancers. Clin Chim Acta 457, 130-136.
Tian, Y., Li, Y., Shao, Y. and Zhang, Y. (2020) Gene modification strategies for next-generation CAR T
cells against solid cancers. J. Hematol. Oncol 13, 54.
Vito, A.D., Orecchia, P., Balza, E., Reverberi, D., Scaldaferri, D., Taramelli, R., Noonan, D.M., Acquati
F and Mortara L. (2020) Overexpression of murine rnaset2 in a colon syngeneic mouse carcinoma model
leads to rebalance of intra-tumor m1/m2 macrophage ratio, activation of t cells, delayed tumor growth,
and rejection. Cancers 12, 717.
Vivek, N., Julie, S.B.B, In-Young, J., Simon, F.L., Andrew, J.R., Megan, M.D., Wei-Ting, H., Priti,
L., Erica, L.C., Shannon, L.M., et al. (2022) PSMA-targeting TGFβ-insensitive armored CAR T cells in
metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28, 724-734.
Wang, L.L., Gray, T., Liu, E., Corder, A., Mei, Z., Robertson, C., et al. (2015) Human Epidermal Growth
Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the
Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol 33, 1688-1696.
Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., Mineno, J., Takesako, K., Kato, T. and
Shiku, H. (2016) Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells
53
associated with symptoms of mild cytokine release syndrome. OncoImmunology 5, e1211218.
Yao, W., Maitra, A. and Ying, H. (2020) Recent insights into the biology of pancreatic cancer.
EBioMedicine 53, 102655.
Yunzhen, Q., Yitao, G., Zhiyao, F., Guopei, L., Qiuyi, H., Shengming, D., He, C., Kaizhou, J., Quanxing,
N., Xianjun, Y., et al. (2020) Molecular alterations and targeted therapy in pancreatic ductal
adenocarcinoma. J Hematol Oncol 13, 130.
Zhang, E., Yang, P., Gu, J., Wu, H., Chi, X., Liu, C., Wang, Y., Xue, J., Qi, W., Sun, Q., et al. (2018)
Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J
Hematol Oncol 11, 102.
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D.C., Song, X., Zhang, J., Seth, S., Chow, C.W., Cao, Y. and
Gumbs, C. (2015) Intra-tumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multiregion Sequencing. Science 72, 377-385.
国立研究開発法人国立がん研究センター (2022) がんの統計 2022. In がん情報サービス,
https://ganjoho.jp/public/index.html (2023年3月1日参照)
54
...
論文の公開元へ
